{"filing":{"accession_number":"0001828316-26-000039","cik":"0001828316","ticker":"PHAR","company_name":"Pharming Group N.V.","form":"6-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"pharmingannouncespositivep.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm"},"events":[{"id":34137,"run_id":31406,"accession_number":"0001828316-26-000039","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces positive Phase II topline data for leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation, including favorable safety and tolerability results and clinical improvements such as 26.4% mean spleen volume reduction. This is a material clinical development milestone for a drug candidate under regulatory review, but it does not fit the discrete event categories (not earnings, M\u0026A, executive change, impairment, litigation, or debt-related). It is an operational/strategic advancement in the company's clinical pipeline that would affect a reasonable investor's assessment of the registrant's prospects.","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-22","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":37792,"accession_number":"0001828316-26-000039","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase II topline data for leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation, including favorable safety and tolerability results and clinical improvements such as 26.4% mean spleen volume reduction. This is a material clinical development milestone for a drug candidate under regulatory review, but it does not fit the discrete event categories (not earnings, M\u0026A, executive change, impairment, litigation, or debt-related). It is an operational/strategic advancement in the company's clinical pipeline that would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-22T10:06:08.900762+00:00","company_name":"Pharming Group N.V.","ticker":"PHAR","filing_date":"2026-09-22"}]}